Generative AI in Biopharma: Transforming Discovery to Market Applications
Translational medicine teams at organizations like Moderna, Roche, and AstraZeneca face a common operational reality: the path from target identification to approved therapy involves navigating hundreds of decision points, each constrained by incomplete information, resource limits, and regulatory requirements. A discovery biologist selecting which hit compounds merit lead optimization must balance binding affinity, selectivity, ADMET predictions, synthetic accessibility, and patent landscape—a multidimensional optimization problem historically solved through serial experimentation and expert intuition. Clinical development operations teams designing protocols for rare disease studies must predict site feasibility across dozens of geographies with sparse historical data. Regulatory affairs specialists compiling BLA submissions synthesize disparate data sources into coherent narratives under tight PDUFA deadlines. Generative AI in Biopharma offers a fundamentally different approach: sys...